ViroPharma is buying Lev for $442M
Lev Pharma, that focuses on inflammatory diseases is being acquired by ViroPharma for $442 Million. ViroPharma is paying $2.25 per share in cash and 50 cents per share in stock. (read full story at: fiercebiotech.com)
Tags:
lev pharma viropharma pharma biotech
|
Category:
Mergers and Acquisitions
|
Email this
|
ViroPharma is buying Lev for $442M
Lev Pharma, that focuses on inflammatory diseases is being acquired by ViroPharma for $442 Million. ViroPharma is paying $2.25 per share in cash and 50 cents per share in stock. (read full story at: fiercebiotech.com)
Submitted by:
| © 2007 StartupNewz.com | Login | Join | Top Users | Tag Cloud | FAQ | Contact us | Silicon Valley Blog | Podcasts | Photo Album | XHTML CSS |
Comments